{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Disease&page=15",
    "query": {
      "condition": "Acute Disease",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 7829,
    "total_pages": 783,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Disease&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Disease&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T19:28:26.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01065077",
      "title": "BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Heart Failure"
      ],
      "interventions": [
        {
          "name": "Cinaciguat (BAY58-2667)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-03",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2015-10-08",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 6,
      "location_summary": "Ridgewood, New Jersey • Winston-Salem, North Carolina • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Ridgewood",
          "state": "New Jersey"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Fairfield",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01065077"
    },
    {
      "nct_id": "NCT05741112",
      "title": "The Long COVID-19 Wearable Device Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Long COVID",
        "Postural Orthostatic Tachycardia Syndrome",
        "Dysautonomia",
        "Myalgic Encephalomyelitis",
        "Chronic Fatigue Syndrome",
        "Long Covid19"
      ],
      "interventions": [
        {
          "name": "Wearable device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Scripps Translational Science Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100500,
      "start_date": "2023-11-16",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05741112"
    },
    {
      "nct_id": "NCT01457430",
      "title": "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Icatibant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2011-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-18",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wheaton",
          "state": "Maryland"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01457430"
    },
    {
      "nct_id": "NCT03590028",
      "title": "An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Early Nephrology Consult (ENC)",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2018-10-01",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03590028"
    },
    {
      "nct_id": "NCT02981628",
      "title": "Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent B Lymphoblastic Lymphoma",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory B Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Asparaginase Erwinia chrysanthemi",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Calaspargase Pegol",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Diagnostic Imaging Testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 80,
      "start_date": "2017-06-19",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 156,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981628"
    },
    {
      "nct_id": "NCT05292274",
      "title": "NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "SARS CoV 2 Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 304,
      "start_date": "2022-03-30",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292274"
    },
    {
      "nct_id": "NCT03092674",
      "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome/Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2018-02-02",
      "completion_date": "2024-06-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 506,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092674"
    },
    {
      "nct_id": "NCT06163690",
      "title": "Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Long COVID",
        "Long Covid19",
        "Post-Acute COVID-19",
        "Post-Acute COVID-19 Syndrome",
        "Long Haul COVID",
        "Long-Haul COVID-19"
      ],
      "interventions": [
        {
          "name": "Endourage Targeted Wellness Formula C™, a full hemp flower extract",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Endourage, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-13",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06163690"
    },
    {
      "nct_id": "NCT01034410",
      "title": "A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "AS1411",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antisoma Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2010-01",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-02-02",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Charleston, South Carolina",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034410"
    },
    {
      "nct_id": "NCT04633889",
      "title": "Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Deferoxamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2021-04-13",
      "completion_date": "2026-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-06T19:28:26.652Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04633889"
    }
  ]
}